C min 502 ng/mL, and AUC 0-10 5400 ng•h/mL, while median T max was 4.17 hours. 5 After administration of 600 mg orally (PO) twice daily, the extrapolated C min of alectinib in cerebrospinal fluid (CSF) and unbound alectinib in plasma were 2.69 nmol/L and 3.12 nmol/L, respectively. 5 The major active metabolite of alectinib, M4, demonstrated steady-state values of C max 246 ng/mL and AUC 0-12 2,810 ng•h/mL. 6 The absolute bioavailability of alectinib under fed conditions is 37%. 6 The apparent volume of distribution (V d ) is 4,016 L for alectinib and 10,093 L for M4. 6 The plasma protein binding of both alectinib and M4 is greater than 99%, the apparent clearance is 81.9 L/h for alectinib and 217 L/h for M4, and the mean elimination half-life (t 1/2 ) is 33 hours for alectinib and 31 hours for M4. 6 Alectinib is metabolized by CYP3A4 to its major active metabolite M4, which is also metabolized by CYP3A4. 6 Ninety-eight percent of alectinib and metabolites is excreted through the feces, with alectinib accounting for 84% and M4 6%; urinary excretion accounts for less than 0.5% of alectinib. 6 Selected therapeutic regimens of alectinib appear in Table 1 . Note: PO = oral. a Conforms to dosing information listed in the manufacturer's labeling.
STABILITY
1. Store below 30°C (86°F). 6 2. The manufacturer recommends that the capsules be kept in the original container until time of administration. 6 ADMINISTRATION 1. Alectinib should be taken orally twice daily with food. Neither the manufacturer nor the studies reviewed specified the exact time interval of twice daily. 2,5-8 2. If a dose of alectinib is missed or vomiting occurs shortly after a dose, take the next dose at its scheduled time. 6 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// ctep.cancer.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
A. Cardiovascular

DOSAGE MODIFICATIONS (ASSuMING A DOSAGE OF 600 MG ORALLY TwICE DAILY)
A. Hepatic: 1. For ALT or AST elevations greater than 5 times the upper limit of normal (ULN) with total bilirubin less than or equal to 2 times ULN, hold alectinib until recovery of ALT/ AST to less than or equal to 3 times ULN, then resume at 450 mg twice daily. 6 
For ALT or AST elevations greater than 3
times ULN with total bilirubin greater than 2 times ULN in absence of cholestasis or hemolysis, permanently discontinue alectinib. 6 3. For total bilirubin elevation greater than 3 times ULN, hold alectinib until total bilirubin is less than or equal to 1.5 times ULN, then resume at 450 mg twice daily. 6 B. CPK:
1. For CPK elevation greater than 5 times ULN, hold alectinib until recovery to less than or equal to 2.5 times ULN, then resume at 450 mg twice daily. 6 2. For CPK elevation greater than 10 times ULN or second occurrence of CPK elevation greater than 5 times ULN, hold until recovery to less than or equal to 2.5 times ULN, then resume at 300 mg twice daily. 6
Drug name: Ceritinib
Synonyms: LDK 378, LDK-378, LDK378, NVP-LDK378, Zykadia
MECHANISM OF ACTION
Ceritinib is a small-molecule tyrosine kinase inhibitor that inhibits several targets. Ceritinib's primary mechanism of action is phosphorylation of the anaplastic lymphoma kinase (ALK) and ALKmediated phosphorylation of STAT3, suppressing downstream signaling pathways and causing inhibition of ALK-positive cells. Ceritinib also inhibits insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1; it does not inhibit MET. [9] [10] [11] [12] 
PHARMACOKINETICS
Ceritinib is highly (97%) protein bound; the V d is 4,230 L. 10 The C max is 800 ± 205 ng/mL at approximately 4 to 6 hours following a single dose of 750 mg. At day 8, the mean AUC was 16,500 ± 4,750 ng•mL/h; steady-state concentration is reached at about day 15. The mean terminal half-life (T 1/2 ) is approximately 40 to 41 hours. 12 Ceritinib is metabolized in the liver primarily by the CYP3A isoenzyme. 11 Approximately 92% of the drug is excreted in the feces (68% as unchanged drug); 1.3% is excreted in the urine. 10 Selected therapeutic regimens of ceritinib appear in Table 2 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the NCI Common Terminology Criteria for Adverse Events (http://ctep. cancer.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Acute pericarditis 33%. 13 B. Constitutional: Fatigue (grade 2) 33% to 36%, 13, 20 (grade 3 or 4) 5% to 10% 12 ; fever 26%. 18 C. Endocrine/Metabolic: Hyperglycemia 2% to 4%, 12 hypophosphatemia (grade 3 or 4) 3% to 10%, 12 increased alkaline phosphatase (grade 3 or 4) 2% to 20%. 12 D. Gastrointestinal: Anorexia 41% 18 ; diarrhea/ abdominal discomfort (grade 1 or 2) 33% 13 ; diarrhea 80% to 86%, [16] [17] [18] 20 (grade 1) 33%, 13 (grade 3 or 4) 7% to 10% 12, 18 ; increased amylase (grade 3 or 4) 2% to 10% 12 ; nausea 54% to 81%, 16, 17, 20 (grade 3 or 4) 5% to 10% 12 ; nausea (grade 3 or 4) 5% to 10% 12 ; vomiting 63% to 82%, 16, 18, 20 (grade 1) 33%, 13 (grade 3 or 4) 5% to 10%. 12 E. Hepatic: Increased ALT 36% to 46%, 18, 20 
MECHANISM OF ACTION
Signaling lymphocyte activation molecule family member 7 (SLAMF7), also known as CS1, CD2 subset-1, CD2-like receptor-activating cytotoxic cell (CRACC), and CD319, is a glycosylated cell surface protein that is highly and uniformly expressed on primary multiple myeloma cells. It is also expressed at lower levels on natural killer (NK) cells. Engagement of SLAMF7 on NK cells and myeloma cells by SLAMF7-specific antibodies results in enhanced antibody-directed cellular cytotoxicity of NK cells against primary multiple myeloma cells. Elotuzumab is a humanized monoclonal immunoglobulin G antibody that targets SLAMF7. In vitro studies show that elotuzumab enhances the antibody-dependent cellular cytotoxicity of NK cells Volume 51, July-August 2016 against myeloma cells and that this effect is further amplified if elotuzumab is given with lenalidomide. 21, 22 
PHARMACOKINETICS
Mean pharmacokinetic parameters after a single intravenous (IV) infusion of elotuzumab 10 mg/ kg were T 1/2 4.6 days, T max 4.2 hours, C max 337.4 mcg/mL, V d 2976.9 mL, CL 15.3 mL/h, and AUC inf 28,378.2 mcg•h/mL. 23 When given in combination with lenalidomide 25 mg PO once daily and dexamethasone 40 mg PO once weekly, mean pharmacokinetic parameters after a single dose of IV elotuzumab 10 mg/kg in patients with normal renal function (CrCl ≥ 90 mL/min) were C max 217 mcg/ mL, AUC inf 46,401 mcg•h/mL, and total body CL 0.22 mL/h/kg. In patients with serious renal impairment (CrCl < 30 mL/min) given elotuzumab, lenalidomide (with renal dose reductions), and dexamethasone in the same fashion, there were no significant differences in these pharmacokinetic parameters compared with the patients with normal renal function. 24 Selected therapeutic regimens of elotuzumab appear in Table 3 .
PREPARATION
Follow institutional policies for preparation of haz-
ardous medications when preparing elotuzumab. 2. Use elotuzumab lyophilized powder for reconstitution.
3. Reconstitute the 300 mg vial with 13 mL of sterile water for injection (SWFI) and the 400 mg vial with 17 mL of SWFI to produce drug to a concentration of 25 mg/mL. 25 4. After addition of SWFI, the vial may be inverted or swirled, but vigorous agitation should be avoided. 25 5. Dilute the drug in 230 mL 0.9% sodium chloride (NS) injection or 5% dextrose injection (D5W) for intravenous infusion. 25 STABILITY 1. Store elotuzumab vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. 25 2. Diluted solutions are stable for no more than 24 hours refrigerated at 2ºC to 8ºC (36ºF to 46ºF) and protected from light and no more than 8 hours at room temperature of 20ºC to 25ºC (68ºF to 77ºF). 25 
ADMINISTRATION
1. Patients should be premedicated with a steroid, H1 and H2 antagonist, and acetaminophen prior to administration of elotuzumab. The manufacturer recommends the following regimen 25 : A. Dexamethasone: 28 mg PO between 3 and 24 hours prior to elotuzumab and 8 mg IV between 45 and 90 minutes before elotuzumab. B. An H 1 blocker, H 2 blocker, and acetaminophen premedication between 45 and 90 minutes before elotuzumab. 2. Infuse elotozumab through a 0.2 to 1.2 micron low-protein-binding filter. 25 3. The first dose of elotuzumab should be infused at 0.5 mL/min for the first 30 minutes, 1 mL/min for the next 30 to 60 minutes, and 2 mL/min for any infusion time over 60 minutes. 25 
4.
The second dose of elotuzumab should be infused at 1 mL/min for the first 30 minutes and 2 mL/ min for any infusion time over 30 minutes. All subsequent doses may be infused at 2 mL/min. 25 
For grade 2 or higher infusion reactions, stop
the infusion. Upon resolution of infusion reaction to grade 1 or lower, resume infusion at 0.5 mL/min and gradually increase the infusion rate by 0.5 mL/min every 30 minutes until the rate at which the infusion reaction occurred is reached. If the infusion reaction does not recur, then infusion rate escalation may continue as described in 3 above. If the infusion reaction recurs, do not restart the infusion on that day. 25
TOXICITIES
The data below are presented as toxicity rates for elotuzumab alone and for elotuzumab and lenalidomide and dexamethasone. The combination of elotuzumab and lenalidomide and dexamethasone is the only FDA-approved use of elotuzumab.
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the NCI Common Terminology Criteria for Adverse Events (http://ctep.cancer.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
Elotuzumab Alone
Drug name: Venetoclax
Synonyms: ABT-199, GDC-0199, Venclexta
MECHANISM OF ACTION
Venetoclax inhibits the BCL2 protein by mimicking BH3 protein, one of the BCL2 targets. Inhibition of BCL2 results in increased apoptosis in malignant cells. 28 
PHARMACOKINETICS
Following a single dose of 20 to 200 mg PO, the mean T max was 6 to 8 hours, the mean maximum concentration (C max ) was 0.07 to 1.15 mcg/mL. The mean terminal T ½ was 16.9 to 40.9 hours; the mean AUC was 2.0 to 49.5 mcg•h/mL. 29 At steady state, oral doses of 100 to 800 mg daily, the mean T max was 5 to 8 hours, and the mean C max was 1.58 to 2.99 mcg/mL. The mean area under the time versus concentration curve (AUC) was 22 to 46 mcg•h/mL. 29 Other investigators report the T max as 6 to 8 hours and the T½ as 15 to 19 hours, respectively. 30, 31 The drug is highly bound (>99%) to plasma proteins, with a V d of 256 to 321 L. The T½ is approximately 26 hours. Venetoclax is metabolized in the liver, primarily by CYP3A4/5. The major metabolite, M27, is much less active than the parent drug. More than 99.9% of the drug is excreted in the feces; less than 0.1% is found in the urine within 9 days. About 20.8% of the dose is excreted as unchanged drug. 32 Selected therapeutic regimens of venetoclax appear in Table 4 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the NCI Common Terminology Criteria for Adverse Events (http://ctep.cancer.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 29 ; insomnia 28% to 33% [36] [37] [38] ; syncope (grade 3 or 4) 15%. 33 C. Constitutional: Asthenia 20% to 29% 34, 38 ; fatigue 16% to 44%, [29] [30] [31] 34, 35, 37, 39, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] (grade 3 or 4) 3%
